Advertisement

The Impact of Infection During Pregnancy on the Mother and Baby

  • C. R. Robert George
  • Monica M. Lahra
  • Heather E. JefferyEmail author

Abstract

Maternal and newborn health are strongly linked. Infection is a recognized and prominent underlying cause of both maternal and newborn pathologies. Consequently, preventive strategies and many evidence-based interventions directed toward the mother can benefit both the mother and baby. Infection continues to account for a major proportion of maternal, fetal, and neonatal mortality and morbidity worldwide. About 40 % of maternal deaths result from infection while an additional 14.5 % of maternal deaths result from abortion, often with underlying sepsis causing death. Of the three major causes of neonatal deaths (infection, prematurity, intrapartum-related deaths), infection is responsible for 28 % and preterm birth complications are responsible for 14 %. Infection is both an underlying cause of preterm birth and a major cause of complications and death in mothers and babies.

Keywords

Urinary tract infection (UTI) Pneumonia Bacterial vaginosis Candidiasis Trichomoniasis Chlamydia Gonorrhea Syphilis Tuberculosis Group A Streptococcus (GAS) Group B Streptococcus (GBS) Listeriosis Toxoplasmosis Malaria Parvovirus B19 Rubella Cytomegalovirus (CMV) Varicella-zoster virus (VZV) Human herpes simplex virus (HSV) HSV-1 HSV-2 Human immunodeficiency virus (HIV) HIV Type 1 (HIV-1) HIV Type 2 (HIV-2) Maternal infection Neonatal infection Perinatal infection 

References

  1. 1.
    Lassi ZS, Majeed A, Rashid S, Yakoob MY, Bhutta ZA. The interconnections between maternal and newborn health–evidence and implications for policy. J Matern Fetal Neonatal Med. 2013;26:3–53.PubMedGoogle Scholar
  2. 2.
    Bhutta ZA, Black RE. Global maternal, newborn, and child health–so near and yet so far. N Engl J Med. 2013;369:2226–35.PubMedGoogle Scholar
  3. 3.
    Wang H, Liddell CA, Coates MM, Mooney MD, Levitz CE, Schumacher AE, et al. Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2014;384:957–79.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Meads C. Screening for asymptomatic bacteriuria in pregnancy: external review against programme appraisal criteria for the UK National Screening Committee (UK NSC). Version: 2: UK National Screening Committee. 2011. Available from: http://www.screening.nhs.uk/policydb_download.php?doc=169.
  5. 5.
    Wing DA, Fassett MJ, Getahun D. Acute pyelonephritis in pregnancy: an 18-year retrospective analysis. Am J Obstet Gynecol. 2014;210:219.e211–6.Google Scholar
  6. 6.
    Le J, Briggs GG, McKeown A, Bustillo G. Urinary tract infections during pregnancy. Ann Pharmacother. 2004;38:1692–701. Review.PubMedGoogle Scholar
  7. 7.
    Grabe M, Bartoletti R, Bjerklund-Johansen TE, Çek HM, Pickard RS, Tenke P, et al. Guidelines on urological infections: European Association of Urology. 2014. Available from: http://uroweb.org/wp-content/uploads/19-Urological-infections_LR.pdf.
  8. 8.
    Lee M, Bozzo P, Einarson A, Koren G. Urinary tract infections in pregnancy. Can Fam Physician Med Fam Can. 2008;54:853–4.Google Scholar
  9. 9.
    Verani JR, McGee L, Schrag SJ, Division of Bacterial Diseases NCfI, Respiratory Diseases CfDC, Prevention. Prevention of perinatal group B streptococcal disease – revised guidelines from CDC, 2010. MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep/Cent Dis Control. 2010;59:1–36.Google Scholar
  10. 10.
    Smaill FM, Vazquez JC. Antibiotics for asymptomatic bacteriuria in pregnancy. Cochrane Database of Systematic Reviews 2007, Issue 2. Art. No.: CD000490. doi:  10.1002/14651858.CD000490.pub2.
  11. 11.
    Sheffield JS, Cunningham FG. Community-acquired pneumonia in pregnancy. Obstet Gynecol. 2009;114:915–22.PubMedGoogle Scholar
  12. 12.
    Lim W, Macfarlane J, Colthorpe C. Pneumonia and pregnancy. Thorax. 2001;56:398–405.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Laibl VR, Sheffield JS. Influenza and pneumonia in pregnancy. Clin Perinatol. 2005;32:727–38.PubMedGoogle Scholar
  14. 14.
    Romero R, Hassan SS, Gajer P, Tarca AL, Fadrosh DW, Nikita L, et al. The composition and stability of the vaginal microbiota of normal pregnant women is different from that of non-pregnant women. Microbiome. 2014;2:4.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2013;1:CD000262.Google Scholar
  16. 16.
    Yudin MH. Bacterial vaginosis in pregnancy: diagnosis, screening, and management. Clin Perinatol. 2005;32:617–27.PubMedGoogle Scholar
  17. 17.
    Bradshaw C, Morton A, Garland S, et al. Higher risk behavioural practices associated with bacterial vaginosis compared with vaginal candidiasis. Obstet Gynecol. 2005;106:105–14.PubMedGoogle Scholar
  18. 18.
    Blackwell AL. Vaginal bacterial phaginosis? Sex Transm Infect. 1999;75:352–3.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983;74:14–22.PubMedGoogle Scholar
  20. 20.
    Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol. 1991;29:297–301.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010;59:1–110.PubMedGoogle Scholar
  22. 22.
    Sobel JD. Vulvovaginal candidosis. Lancet. 2007;369:1961–71.PubMedGoogle Scholar
  23. 23.
    Foxman B, Muraglia R, Dietz JP, Sobel JD, Wagner J. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Low Genit Tract Dis. 2013;17:340–5.PubMedGoogle Scholar
  24. 24.
    Carr P, Felsenstein D, Friedman R. Evaluation and management of vaginitis. J Gen Intern Med. 1998;13:335–46.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Chaim W, Mazor M, Wiznitzer A. The prevalence and clinical significance of intraamniotic infection with candida species in women with preterm labor. Arch Gynecol Obstet. 1992;251:9–15.PubMedGoogle Scholar
  26. 26.
    Leibovitz E, Livshiz-Riven I, Borer A, Taraboulos-Klein T, Zamir O, Shany E, et al. A prospective study of the patterns and dynamics of colonization with Candida spp. In very low birth weight neonates. Scand J Infect Dis. 2013;45:842–8.PubMedGoogle Scholar
  27. 27.
    Therapeutic Guidelines. Vulvovaginal candidiasis [revised 2009, amended 2010]. Etg complete [internet]. Melbourne: Therapeutic Guidelines Limited; 2014.Google Scholar
  28. 28.
    Young G, Jewell D. Topical treatment for vaginal candidiasis (thrush) in pregnancy. Cochrane Database Syst Rev. 2001;(4):CD000225.Google Scholar
  29. 29.
    Cassone A. Development of vaccines for Candida albicans: fighting a skilled transformer. Nat Rev Microbiol. 2013;11:884–91.PubMedGoogle Scholar
  30. 30.
    Kiss H, Petricevic L, Husslein P. Prospective randomised controlled trial of an infection screening programme to reduce the rate of preterm delivery. BMJ. 2004;329:371–5.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Van der Pol B. Trichomonas vaginalis infection: the most prevalent nonviral sexually transmitted infection receives the least public health attention. Clin Infect Dis. 2007;44:23–5.PubMedGoogle Scholar
  32. 32.
    Gaydos CA, Hsieh YH, Barnes M, Quinn N, Agreda P, Jett-Goheen M, et al. Trichomonas vaginalis infection in women who submit self-obtained vaginal samples after internet recruitment. Sex Transm Dis. 2011;38:828–32.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Cotch M, Pastorek J, Nugent R. Demographic and behavioural predictors of Trichomonas vaginalis infection among pregnant women. The vaginal infections and prematurity study group. Obstet Gynecol. 1991;78:1087–92.Google Scholar
  34. 34.
    Soper D. Trichomoniasis: under control or undercontrolled? Am J Obstet Gynecol. 2004;190:281–90.PubMedGoogle Scholar
  35. 35.
    Risser WL, Bortot AT, Benjamins LJ, Feldmann JM, Barratt MS, Eissa MA, et al. The epidemiology of sexually transmitted infections in adolescents. Semin Pediatr Infect Dis. 2005;16:160–7.PubMedGoogle Scholar
  36. 36.
    Coleman JS, Gaydos CA, Witter F. Trichomonas vaginalis vaginitis in obstetrics and gynecology practice: new concepts and controversies. Obstet Gynecol Surv. 2013;68:43–50.Google Scholar
  37. 37.
    Kissinger P, Adamski A. Trichomonas vaginalis and HIV interactions: a review. Sex Transm Infect. 2013;89:426–33.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Zhang ZF, Begg CB. Is Trichomonas vaginalis a cause of cervical neoplasia? Results from a combined analysis of 24 studies. Int J Epidemiol. 1994;23:682–90.PubMedGoogle Scholar
  39. 39.
    Huppert JS, Mortensen JE, Reed JL, Kahn JA, Rich KD, Miller WC, et al. Rapid antigen testing compares favorably with transcription-mediated amplification assay for the detection of Trichomonas vaginalis in young women. Clin Infect Dis. 2007;45:194–8.PubMedGoogle Scholar
  40. 40.
    Kirkcaldy RD, Augostini P, Asbel LE, Bernstein KT, Kerani RP, Mettenbrink CJ, et al. Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD Surveillance Network, 2009–2010. Emerg Infect Dis. 2012;18:939–43.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Gulmezoglu AM, Azhar M. Interventions for trichomoniasis in pregnancy. The Cochrane Database Syst Rev. 2011;(5):CD000220.Google Scholar
  42. 42.
    Koss CA, Baras DC, Lane SD, Aubry R, Marcus M, Markowitz LE, et al. Investigation of metronidazole use during pregnancy and adverse birth outcomes. Antimicrob Agents Chemother. 2012;56:4800–5.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Lichtenstein B, Desmond RA, Schwebke JR. Partnership concurrency status and condom use among women diagnosed with Trichomonas vaginalis. Womens Health Issues. 2008;18:369–74.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Carey AJ, Beagley KW. Chlamydia trachomatis, a hidden epidemic: effects on female reproduction and options for treatment. Am J Reprod Immunol. 2010;63:576–86.PubMedGoogle Scholar
  45. 45.
    Somboonna N, Mead S, Liu J, Dean D. Discovering and differentiating new and emerging clonal populations of Chlamydia trachomatis with a novel shotgun cell culture harvest assay. Emerg Infect Dis. 2008;14:445–53.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Braxton J, Carey D, Davis D, Footman A, Flagg E, Grier L, et al. Sexually transmitted disease surveillance 2012. Atlanta: Centers for Disease Control and Prevention; 2014.Google Scholar
  47. 47.
    Peipert JF. Clinical practice. Genital chlamydial infections. N Engl J Med. 2003;349:2424–30.PubMedGoogle Scholar
  48. 48.
    Workowski KA, Berman S, Centers for Disease C, Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep Morb Mortal Wkly Rep Recom Rep/Cent Dis Control. 2010;59:1–110.Google Scholar
  49. 49.
    Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ. 2004;82:454–61.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2012. Atlanta: Centers for Disease Control and Prevention; 2014.Google Scholar
  51. 51.
    Hafner LM, Wilson DP, Timms P. Development status and future prospects for a vaccine against Chlamydia trachomatis infection. Vaccine. 2014;32:1563–71.PubMedGoogle Scholar
  52. 52.
    Bourne C, Lahra MM, Donovan B. Gaining control of gonorrhoea. Med Today. 2014;15:58–60.Google Scholar
  53. 53.
    Brocklehurst P. Update on the treatment of sexually transmitted infections in pregnancy–1. Int J STD AIDS. 1999;10:571–8.PubMedGoogle Scholar
  54. 54.
    Edwards J, Apicella M. The molecular mechanisms used by Neisseria gonorrhoeae to initiate infection differ between men and women. Clin Microbiol Rev. 2004;17:965–81.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Bignell CJ. European guidelines for the management of gonorrhea. Int J STD AIDS. 2001;12:27–9.PubMedGoogle Scholar
  56. 56.
    Hedges S, Mayo M, Mestecky J, et al. Limited local and systemic antibody response to Neisseria gonorrhoeae during uncomplicated genital infections. Infect Immun. 1999;67:3937–46.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Goire N, Lahra MM, Chen M, Donovan B, Fairley CK, Guy R, et al. Molecular approaches to enhance surveillance of gonococcal antimicrobial resistance. Nat Rev Microbiol. 2014;12:223–9.PubMedGoogle Scholar
  58. 58.
    Newman L, Kamb M, Hawkes S, Gomez G, Say L, Seuc A, et al. Global estimates of syphilis in pregnancy and associated adverse outcomes: analysis of multinational antenatal surveillance data. PLoS Med. 2013;10:e1001396.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Patton ME, Su JR, Nelson R, Weinstock H, (CDC). Primary and secondary syphilis–United States, 2005–2013. MMWR Morb Mortal Wkly Rep. 2014;63:402–6.Google Scholar
  60. 60.
    Berman SM. Maternal syphilis: pathophysiology and treatment. Bull World Health Organ. 2004;82:433–8.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Zeltser R, Kurban AK. Syphilis. Clin Dermatol. 2004;22:461–8.PubMedGoogle Scholar
  62. 62.
    Gomez GB, Kamb ML, Newman LM, Mark J, Broutet N, Hawkes SJ. Untreated maternal syphilis and adverse outcomes of pregnancy: a systematic review and meta-analysis. Bull World Health Organ. 2013;91:217–26.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Saloojee H, Velaphi S, Goga Y, Afadapa N, Steen R, Lincetto O. The prevention and management of congenital syphilis: an overview and recommendations. Bull World Health Organ. 2004;82:424–30.PubMedPubMedCentralGoogle Scholar
  64. 64.
    Peeling RW, Ye H. Diagnostic tools for preventing and managing maternal and congenital syphilis: an overview. Bull World Health Organ. 2004;82:439–46.PubMedPubMedCentralGoogle Scholar
  65. 65.
    Herremans T, Kortbeek L, Notermans DW. A review of diagnostic tests for congenital syphilis in newborns. Eur J Cli Microbiol Infect Dis. 2010;29:495–501.Google Scholar
  66. 66.
    Sena AC, White BL, Sparling PF. Novel Treponema pallidum serologic tests: a paradigm shift in syphilis screening for the 21st century. Clin Infect Dis. 2010;51:700–8.PubMedGoogle Scholar
  67. 67.
    Blencowe H, Cousens S, Kamb M, Berman S, Lawn JE. Lives saved tool supplement detection and treatment of syphilis in pregnancy to reduce syphilis related stillbirths and neonatal mortality. BMC Public Health. 2011;11:S9.PubMedPubMedCentralGoogle Scholar
  68. 68.
    Schmid G. Economic and programmatic aspects of congenital syphilis prevention. Bull World Health Organ. 2004;82:402–9.PubMedPubMedCentralGoogle Scholar
  69. 69.
    Hawkes S, Matin N, Broutet N, Low N. Effectiveness of interventions to improve screening for syphilis in pregnancy: a systematic review and meta-analysis. Lancet Infect Dis. 2011;11:684–91.PubMedGoogle Scholar
  70. 70.
    Laibl VR, Sheffield JS. Tuberculosis in pregnancy. Clin Perinatol. 2005;32:739–47.PubMedGoogle Scholar
  71. 71.
    World Health Organization. Global tuberculosis report 2013. Geneva: World Health Organization; 2013.Google Scholar
  72. 72.
    Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis. Lancet. 2003;362:887–99.PubMedGoogle Scholar
  73. 73.
    Smith KC. Congenital tuberculosis: a rare manifestation of a common infection. Curr Opin Infect Dis. 2002;15:269–74.PubMedGoogle Scholar
  74. 74.
    Mnyani CN, McIntyre JA. Tuberculosis in pregnancy. BJOG Int J Obstet Gynaecol. 2011;118:226–31.Google Scholar
  75. 75.
    Zenner D, Kruijshaar ME, Andrews N, Abubakar I. Risk of tuberculosis in pregnancy: a national, primary care-based cohort and self-controlled case series study. Am J Respir Crit Care Med. 2012;185:779–84.PubMedGoogle Scholar
  76. 76.
    Adhikari M. Tuberculosis and tuberculosis/HIV co-infection in pregnancy. Semin Fetal Neonatal Med. 2009;14:234–40.PubMedGoogle Scholar
  77. 77.
    Tb CARE I. International standards for tuberculosis care. The Hague: TB CARE I; 2014.Google Scholar
  78. 78.
    Guerra RL, Hooper NM, Baker JF, Alborz R, Armstrong DT, Maltas G, et al. Use of the amplified Mycobacterium tuberculosis direct test in a public health laboratory: test performance and impact on clinical care. Chest. 2007;132:946–51.PubMedGoogle Scholar
  79. 79.
    Neralla S, Glassroth J. Mycobacterium tuberculosis: the treatment of active disease. Semin Respir Infect. 2003;18:292–306.PubMedGoogle Scholar
  80. 80.
    Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2012. Atlanta: Centers for Disease Control and Prevention; 2013.Google Scholar
  81. 81.
    Centers for Disease Control and Prevention. TB elimination: tuberculosis and pregnancy. Atlanta: Centers for Disease Control and Prevention; 2011.Google Scholar
  82. 82.
    Getahun H, Sculier D, Sismanidis C, Grzemska M, Raviglione M. Prevention, diagnosis, and treatment of tuberculosis in children and mothers: evidence for action for maternal, neonatal, and child health services. J Infect Dis. 2012;205:S216–27.PubMedGoogle Scholar
  83. 83.
    World Health Organization. The Stop TB Strategy: building on and enhancing dots to meet the TB-related millennium development goals. Geneva: World Health Organization; 2006.Google Scholar
  84. 84.
    Sitkiewicz I, Hryniewicz W. Pyogenic streptococci–danger of re-emerging pathogens. Pol J Microbiol. 2010;59:219–26.PubMedGoogle Scholar
  85. 85.
    Vlaminckx BJ, Schuren FH, Montijn RC, Caspers MP, Beitsma MM, Wannet WJ, et al. Dynamics in prophage content of invasive and noninvasive M1 and M28 Streptococcus pyogenes isolates in the Netherlands from 1959 to 1996. Infect Immunol. 2007;75:3673–9.Google Scholar
  86. 86.
    Brown EJ. The molecular basis of streptococcal toxic shock syndrome. N Engl J Med. 2004;350:2093–4.PubMedGoogle Scholar
  87. 87.
    Maharaj D. Puerperal pyrexia: a review. Part i. Obstet Gynecol Surv. 2007;62:393–9.PubMedGoogle Scholar
  88. 88.
    Hamilton SM, Stevens DL, Bryant AE. Pregnancy-related group A streptococcal infections: temporal relationships between bacterial acquisition, infection onset, clinical findings, and outcome. Clin Infect Dis. 2013;57:870–6.PubMedPubMedCentralGoogle Scholar
  89. 89.
    Saab J, Bell SM, Lahra MM. Vaginal carriage rate of streptococcal pyogenes in 1600 pregnant women. Pathology. 2012;44:567–8.PubMedGoogle Scholar
  90. 90.
    Chuang I, Van Beneden C, Beall B, Schuchat A. Population-based surveillance for postpartum invasive group A Streptococcus infections, 1995–2000. Clin Infect Dis. 2002;35:665–70.PubMedGoogle Scholar
  91. 91.
    Mason KL, Aronoff DM. Postpartum group A Streptococcus sepsis and maternal immunology. Am J Reprod Immunol. 2012;67:91–100.PubMedGoogle Scholar
  92. 92.
    Ingham SC, Wadhera RK, Chu CH, DeVita MD. Survival of Streptococcus pyogenes on foods and food contact surfaces. J Food Prot. 2006;69:1159–63.PubMedGoogle Scholar
  93. 93.
    Royal College of Obstetricians and Gynaecologists. Green-top guideline no. 64b: bacterial sepsis following pregnancy. Royal College of Obstetricians and Gynaecologists, London: 2012. Available from: https://www.ranzcog.edu.au/doc/rcog-bacterial-sepsis-following-pregnancy.html.
  94. 94.
    NSW Agency for Clinical Information. Adult sepsis pathway. 2011. Available from: http://www.cec.health.nsw.gov.au/__data/assets/pdf_file/0008/259415/adult-sepsis-pathway-for-emergency-departments.pdf.
  95. 95.
    Stevens DL. Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerg Infect Dis. 1995;1:69–78.PubMedPubMedCentralGoogle Scholar
  96. 96.
    Health Protection Agency Group A Streptococcus Working Group. Interim UK guidelines for management of close community contacts of invasive group A streptococcal disease. Commun Dis Public Health. 2004;7:354–61.Google Scholar
  97. 97.
    Steer JA, Lamagni T, Healy B, Morgan M, Dryden M, Rao B, et al. Guidelines for prevention and control of group a streptococcal infection in acute healthcare and maternity settings in the UK. J Infect. 2012;64:1–18.PubMedGoogle Scholar
  98. 98.
    New South Wales Department of Health. Factsheet: Maternal sepsis (Puerperal fever) due to Group A Streptococcus – information for clinicians. 2012. Available from: http://www.health.nsw.gov.au/Infectious/factsheets/Pages/Maternal_sepsis.aspx.
  99. 99.
    Queensland Health. Queensland Health Guidelines for Public Health Units: Invasive group A Streptococcal disease. 2012. Available from https://www.health.qld.gov.au/cdcg/index/igas.asp.
  100. 100.
    Bisharat N, Crook D, Leigh J, et al. Hyperinvasive neonatal group B Streptococcus has arisen from a bovine ancestor. J Clin Microbiol. 2004;42:2161–7.PubMedPubMedCentralGoogle Scholar
  101. 101.
    Ohlsson A, Shah VS. Intrapartum antibiotics for known maternal Group B Streptococcal colonization. Cochrane Database Syst Rev. 2014;6:CD007467.Google Scholar
  102. 102.
    Edmond KM, Kortsalioudaki C, Scott S, Schrag SJ, Zaidi AK, Cousens S, et al. Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet. 2012;379:547–56.PubMedGoogle Scholar
  103. 103.
    Jeffery HE. Perinatal group B streptococcal infection: a significant public health problem. Semin Neonatal. 1996;1:77–89.Google Scholar
  104. 104.
    Gibbs R, Schrag S, Schuchat A. Perinatal infections due to group B streptococci. Obstet Gynecol. 2004;104:1062–76.PubMedGoogle Scholar
  105. 105.
    Benitz WE, Gould JB, Druzin ML. Risk factors for early-onset group B streptococcal sepsis: estimation of odds ratios by critical literature review. Pediatrics. 1999;103:e77.PubMedGoogle Scholar
  106. 106.
    Puopolo KM, Draper D, Wi S, Newman TB, Zupancic J, Lieberman E, et al. Estimating the probability of neonatal early-onset infection on the basis of maternal risk factors. Pediatrics. 2011;128:e1155–63.PubMedPubMedCentralGoogle Scholar
  107. 107.
    Baker CJ, Carey VJ, Rench MA, Edwards MS, Hillier SL, Kasper DL, et al. Maternal antibody at delivery protects neonates from early onset group B streptococcal disease. J Infect Dis. 2014;209:781–8.PubMedGoogle Scholar
  108. 108.
    Filleron A, Lombard F, Jacquot A, Jumas-Bilak E, Rodiere M, Cambonie G, et al. Group B streptococci in milk and late neonatal infections: an analysis of cases in the literature. Arch Dis Child Fetal Neonatal Ed. 2014;99:F41–7.PubMedGoogle Scholar
  109. 109.
    Boyer KM, Gotoff SP. Prevention of early-onset neonatal group B streptococcal disease with selective intrapartum chemoprophylaxis. N Engl J Med. 1986;314:1665–9.PubMedGoogle Scholar
  110. 110.
    El Helali N, Giovangrandi Y, Guyot K, Chevet K, Gutmann L, Durand-Zaleski I. Cost and effectiveness of intrapartum group B Streptococcus polymerase chain reaction screening for term deliveries. Obstet Gynecol. 2012;119:822–9.Google Scholar
  111. 111.
    Jeffery HE, Lahra MM. Eight-year outcome of universal screening and intrapartum antibiotics for maternal group B streptococcal carriers. Pediatrics. 1998;101:E2.PubMedGoogle Scholar
  112. 112.
    Puopolo K, Madoff L, Eichenwald E. Early-onset group B streptococcal disease in the era of maternal screening. Pediatrics. 2005;115:1240–6.PubMedGoogle Scholar
  113. 113.
    Schrag SJ, Verani JR. Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: experience in the United States and implications for a potential group B streptococcal vaccine. Vaccine. 2013;31:D20–6.PubMedGoogle Scholar
  114. 114.
    Baker CJ, Edwards MS. Group B streptococcal conjugate vaccines. Arch Dis Child. 2003;88:375–8.PubMedPubMedCentralGoogle Scholar
  115. 115.
    Moore MR, Schrag SJ, Schuchat A. Effects of intrapartum antimicrobial prophylaxis for prevention of group-B-streptococcal disease on the incidence and ecology of early-onset neonatal sepsis. Lancet Infect Dis. 2003;3:201–13.PubMedGoogle Scholar
  116. 116.
    Silver HM. Listeriosis during pregnancy. Obstet Gynecol Surv. 1998;53:737–40.PubMedGoogle Scholar
  117. 117.
    Lamont RF, Sobel J, Mazaki-Tovi S, Kusanovic JP, Vaisbuch E, Kim SK, et al. Listeriosis in human pregnancy: a systematic review. J Perinat Med. 2011;39:227–36.PubMedPubMedCentralGoogle Scholar
  118. 118.
    Centers for Disease C, Prevention. Vital signs: Listeria illnesses, deaths, and outbreaks – United States, 2009–2011. MMWR Morb Mortal Wkly Rep. 2013;62:448–52.Google Scholar
  119. 119.
    Posfay-Barbe KM, Wald ER. Listeriosis. Semin Fetal Neonatal Med. 2009;14:228–33.PubMedGoogle Scholar
  120. 120.
    Cossart P, Toledo-Arana A. Listeria monocytogenes, a unique model in infection biology: an overview. Microbes Infect/Inst Pasteur. 2008;10:1041–50.Google Scholar
  121. 121.
    Southwick F, Purich D. Mechanisms of disease, intracellular pathogenesis of listeriosis. N Engl J Med. 1996;334:770–6.PubMedGoogle Scholar
  122. 122.
    Mylonakis E, Paliou M, Hohmann EL, Calderwood SB, Wing EJ. Listeriosis during pregnancy: a case series and review of 222 cases. Medicine. 2002;81:260–9.PubMedGoogle Scholar
  123. 123.
    U.S. Department of Agriculture Food Safety and Inspection Service. FSIS compliance guideline: controlling Listeria monocytogenes in post-lethality exposed ready-to-eat meat and poultry products. 2014. Available from: https://www.google.com.au/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0CB0QFjAA&url=http%3A%2F%2Fwww.fsis.usda.gov%2Fwps%2Fwcm%2Fconnect%2Fd3373299-50e6-47d6-a577-e74a1e549fde%2FControlling_LM_RTE_Guideline_0912%3FMOD%3DAJPERES&ei=9GCKVYDIJ4jn8AWUypvwCg&usg=AFQjCNE-cn4JFlpvrEfHOV_eUEMfZMd1Qw.
  124. 124.
    Luber P, Crerar S, Dufour C, Farber J, Datta A, Todd ECD. Controlling Listeria monocytogenes in ready-to-eat foods: working towards global scientific consensus and harmonization – recommendations for improved prevention and control. Food Control. 2011;22:1535–49.Google Scholar
  125. 125.
    Jones JL, Kruszon-Moran D, Rivera HN, Price C, Wilkins PP. Toxoplasma gondii seroprevalence in the United States 2009–2010 and comparison with the past two decades. Am J Trop Med Hyg. 2014;90:1135–9.PubMedPubMedCentralGoogle Scholar
  126. 126.
    Dunn D, Wallon M, Peyron F, et al. Mother-to-child transmission of toxoplasmosis risk estimates for clinical counselling. Lancet. 1999;353:1829–33.PubMedGoogle Scholar
  127. 127.
    Kravetz J, Federman D. Toxoplasmosis in pregnancy. Am J Med. 2005;118:212–6.PubMedGoogle Scholar
  128. 128.
    Montoya JG, Rosso F. Diagnosis and management of toxoplasmosis. Clin Perinatol. 2005;32:705–26.PubMedGoogle Scholar
  129. 129.
    Foulon W, Pinon JM, Stray-Pedersen B, Pollak A, Lappalainen M, Decoster A, et al. Prenatal diagnosis of congenital toxoplasmosis: a multicenter evaluation of different diagnostic parameters. Am J Obstet Gynecol. 1999;181:843–7.PubMedGoogle Scholar
  130. 130.
    Centers for Disease Control and Prevention. Parasites – toxoplasmosis (Toxoplasma infection): resources for health professionals. 2014. Available from: http://www.cdc.gov/parasites/toxoplasmosis/health_professionals/index.html.
  131. 131.
    Li XL, Wei HX, Zhang H, Peng HJ, Lindsay DS. A meta analysis on risks of adverse pregnancy outcomes in Toxoplasma gondii infection. PLoS One. 2014;9:e97775.PubMedPubMedCentralGoogle Scholar
  132. 132.
    Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004;363:1965–76.PubMedGoogle Scholar
  133. 133.
    Paquet C, Yudin MH. Toxoplasmosis in pregnancy: prevention, screening, and treatment. J Obstet Gynaecol Can. 2013;35:78–81.PubMedGoogle Scholar
  134. 134.
    Lopez A, Dieta V, Wilson M, Navin TR, Jones JL. Preventing congenital toxoplasmosis. MMWR. 2000;49:59–69.PubMedGoogle Scholar
  135. 135.
    Opsteegh M, Kortbeek TM, Havelaar AH, van der Giessen JW. Intervention strategies to reduce human Toxoplasma gondii disease burden. Clin Infect Dis. 2015;60:101–7.PubMedGoogle Scholar
  136. 136.
    Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis. 2007;7:93–104.PubMedGoogle Scholar
  137. 137.
    World Health Organization. World malaria report: 2013. Geneva: World Health Organization; 2013.Google Scholar
  138. 138.
    Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, et al. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet. 2012;379:413–31.Google Scholar
  139. 139.
    Steketee RW, Nahlen BL, Parise ME, Menendez C. The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg. 2001;64:28–35.PubMedGoogle Scholar
  140. 140.
    Centers for Disease Control and Prevention. Malaria: biology. 2012. Available from: http://www.cdc.gov/malaria/about/biology/.
  141. 141.
    Griffith KS, Lewis LS, Mali S, Parise ME. Treatment of malaria in the United States: a systematic review. JAMA. 2007;297:2264–77.PubMedGoogle Scholar
  142. 142.
    Steketee RW. Pregnancy, nutrition and parasitic diseases. J Nutr. 2003;133:1661S–7.PubMedGoogle Scholar
  143. 143.
    van Geertruyden JP, Thomas F, Erhart A, et al. The contribution of malaria in pregnancy to perinatal mortality. Am J Trop Med Hyg. 2004;71:35–40.PubMedGoogle Scholar
  144. 144.
    Fischer PR. Malaria and newborns. J Trop Pediatr. 2003;49:132–4PubMedGoogle Scholar
  145. 145.
    Duffy PE. Maternal immunization and malaria in pregnancy. Vaccine. 2003;21:3358–61.PubMedGoogle Scholar
  146. 146.
    Lindsay S, Ansell J, Selman C, Cox V, Hamilton K, Walraven G. Effect of pregnancy on exposure to malaria mosquitoes. Lancet. 2000;355:1972.PubMedGoogle Scholar
  147. 147.
    Newman RD, Hailemariam A, Jimma D, et al. Burden of malaria during pregnancy in areas of stable and unstable transmission in ethiopia during a nonepidemic year. J Infect Dis. 2003;187:1765–72.PubMedGoogle Scholar
  148. 148.
    Guyatt H, Snow R. Malaria in pregnancy as an indirect cause of infant mortality in Sub-Saharan Africa. Trans R Soc Trop Med Hyg. 2001;95:569–76.PubMedGoogle Scholar
  149. 149.
    Guyatt HL, Snow RW. Impact of malaria during pregnancy on low birth weight in sub-Saharan Africa. Clin Microbiol Rev. 2004;17:760–9.PubMedPubMedCentralGoogle Scholar
  150. 150.
    Brabin BJ, Romagosa C, Abdelgalil S, Menendez C, Verhoeff FH, McGready R, et al. The sick placenta-the role of malaria. Placenta. 2004;25:359–78.PubMedGoogle Scholar
  151. 151.
    World Health Organization. Guidelines for the treatment of malaria. 2nd ed. Geneva: World Health Organization; 2010.Google Scholar
  152. 152.
    World Health Organization. WHO policy brief for the implementation of intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP). Geneva: World Health Organization; 2014. Available from: http://www.who.int/malaria/publications/atoz/iptp-sp-updated-policy-brief-24jan2014.pdf.
  153. 153.
    Arama C, Troye-Blomberg M. The path of malaria vaccine development: challenges and perspectives. J Intern Med. 2014;275:456–66.PubMedGoogle Scholar
  154. 154.
    Cotter C, Sturrock HJ, Hsiang MS, Liu J, Phillips AA, Hwang J, et al. The changing epidemiology of malaria elimination: new strategies for new challenges. Lancet. 2013;382:900–11.PubMedGoogle Scholar
  155. 155.
    Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet. 1975;1:72–3.PubMedGoogle Scholar
  156. 156.
    Koch WC. Fifth (human parvovirus) and sixth (herpes virus 6) diseases. Curr Opin Infect Dis. 2001;14:343–56.PubMedGoogle Scholar
  157. 157.
    Crowcroft NS, Roth CE, Cohen BJ, Miller E. Guidance for control of parvovirus B19 infection in healthcare settings and the community. J Public Health Med. 1999;21:439–46.PubMedGoogle Scholar
  158. 158.
    Lamont RF, Sobel JD, Vaisbuch E, Kusanovic JP, Mazaki-Tovi S, Kim SK, et al. Parvovirus B19 infection in human pregnancy. BJOG. 2011;118:175–86.PubMedGoogle Scholar
  159. 159.
    Luo Y, Kleiboeker S, Deng X, Qiu J. Human parvovirus B19 infection causes cell cycle arrest of human erythroid progenitors at late S phase that favors viral DNA replication. J Virol. 2013;87:12766–75.PubMedPubMedCentralGoogle Scholar
  160. 160.
    van Beers-Tas MH, Heidema J. Review: Pathogenesis of Parvovirus Infections in Children. Virol Mycol 2013;2:110. doi: 10.4172/2161-0517.1000110.
  161. 161.
    Silingardi E, Santunione AL, Rivasi F, Gasser B, Zago S, Garagnani L. Unexpected intrauterine fetal death in parvovirus B19 fetal infection. Am J Forensic Med Pathol. 2009;30:394–7.PubMedGoogle Scholar
  162. 162.
    Giorgio E, De Oronzo MA, Iozza I, Di Natale A, Cianci S, Garofalo G, et al. Parvovirus B19 during pregnancy: a review. J Prenat Med. 2010;4:63–6.PubMedPubMedCentralGoogle Scholar
  163. 163.
    Corcoran A, Doyle S. Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19. J Med Microbiol. 2004;53:459–75.PubMedGoogle Scholar
  164. 164.
    Anderson MJ, Higgins PG, Davis LR, et al. Experimental parvoviral infection in humans. J Infect Dis. 1985;152:257–65.PubMedGoogle Scholar
  165. 165.
    Young NS, Brown KE. Mechanisms of disease: parvovirus B19. N Engl J Med. 2004;350:586–97.PubMedGoogle Scholar
  166. 166.
    Staroselsky A, Klieger-Grossmann C, Garcia-Bournissen F, Koren G. Exposure to fifth disease in pregnancy. Can Fam Physician Med Fam Canad. 2009;55:1195–8.Google Scholar
  167. 167.
    Levy R, Weissman A, Blomberg G, Hagay ZJ. Infection by parvovirus B19 during pregnancy: a review. Obstet Gynecol Surv. 1997;​52:254–9.PubMedGoogle Scholar
  168. 168.
    Skjoldebrand-Sparre L, Tolfvenstam T, Papadogiannakis N, Wahren B, Broliden K, Nyman M. Parvovirus B19 infection: association with third-trimester intrauterine fetal death. BJOG. 2000;107:476–80.PubMedGoogle Scholar
  169. 169.
    Brown KE, Green SW, Antunez dMJ, et al. Congenital anemia after transplacental parvovirus B19 infection. Lancet. 1994;343:895–6.PubMedGoogle Scholar
  170. 170.
    Crane J, Society of Obstetricians and Gynecologists of Canada. Parvovirus B19 infection in pregnancy. J Obstet Gynaecol Can. 2002;24:727–43.Google Scholar
  171. 171.
    The Royal Hospital for Women. Clinical policies, procedures & guidelines: parvovirus B19 screening and management in pregnancy. 2014. Available from: http://www.seslhd.health.nsw.gov.au/rhw/manuals/documents/Antenatal_Pregnancy%20Care/Parvovirus%20B19%20Screening%20and%20Management%20in%20pregnancy.pdf.
  172. 172.
    Servey JT, Reamy BV, Hodge J. Clinical presentations of parvovirus B19 infection. Am Fam Physician. 2007;75:373–6.PubMedGoogle Scholar
  173. 173.
    Valeur-Jensen AK, Pedersen CB, Westergaard T, Jensen IP, Lebech M, Andersen PK, et al. Risk factors for parvovirus B19 infection in pregnancy. JAMA. 1999;281:1099–105.PubMedGoogle Scholar
  174. 174.
    Gregg NM. Congenital cataract following German measles in the mother. Trans Ophthalmol Soc Aust. 1941;3:35–46.Google Scholar
  175. 175.
    Maldonado YA. Varicella-zoster virus. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 5th ed. New York: Churchill Livingstone; 2000.Google Scholar
  176. 176.
    World Health Organization. Global measles and rubella strategic plan: 2012–2020. Geneva: World Health Organization; 2012.Google Scholar
  177. 177.
    World Health Organization. Fact sheet number 367: rubella. 2014. Available from: http://www.who.int/mediacentre/factsheets/fs367/en/.
  178. 178.
    Plotkin SA. Rubella eradication. Vaccine. 2001;19:3311–9. Review.PubMedGoogle Scholar
  179. 179.
    Centers for Disease Control and Prevention. Elimination of rubella and congenital rubella syndrome – United States, 1969–2004. MMWR Morb Mortal Wkly Rep. 2005;54:279–82.Google Scholar
  180. 180.
    Cooper LZ, Krugman S. Clinical manifestations of postnatal and congenital rubella. Arch Ophthalmol. 1967;77:434–9.PubMedGoogle Scholar
  181. 181.
    Miller E, Cradock-Watson JE, Pollock TM. Consequences of confirmed maternal rubella at successive stages of pregnancy. Lancet. 1982;2:781–94.PubMedGoogle Scholar
  182. 182.
    Banatvala JE, Brown DW. Rubella. Lancet. 2004;363:1127–37.PubMedGoogle Scholar
  183. 183.
    World Health Organization. Surveillance guidelines for measles, rubella and congenital rubella syndrome in the WHO European region. Copenhagen: World Health Organization; 2012.Google Scholar
  184. 184.
    Reef SE, Plotkin S, Cordero JF, Katz M, Cooper L, Schwartz B, et al. Preparing for elimination of congenital rubella syndrome (CRS): summary of a workshop on CRS elimination in the United States. Clin Infect Dis. 2000;31:85–95.PubMedGoogle Scholar
  185. 185.
    Forrest JM, Turnbull FM, Sholler GF, Hawker RE, Martin FJ, Doran TT, et al. Gregg’s congenital rubella patients 60 years later. Med J Aust. 2002;177:664–7.PubMedGoogle Scholar
  186. 186.
    Atkinson W, Hamborsky J, Stanton A, Wolfe C, editors. Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases. Hamborsky J, Kroger A, Wolfe S, eds. 13th ed. Washington DC: Public Health Foundation; 2015.Google Scholar
  187. 187.
    King Edward Memorial Hospital. Clinical guidelines: 1.4.7 rubella in pregnancy. Perth; 2012. Government of Western Australia, Department of Health. Available from: http://kemh.health.wa.gov.au/development/manuals/O&G_guidelines/sectionb/1/b1.4.7.pdf.
  188. 188.
    Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010;20:202–13.PubMedGoogle Scholar
  189. 189.
    Centers for Disease Control and Prevention. Cytomegalovirus (CMV) and congenital CMV infection: congenital CMV infection trends and statistics. 2013. Available from: http://www.cdc.gov/cmv/trends-stats.html.
  190. 190.
    Centers for Disease Control Prevention. Knowledge and practices of obstetricians and gynecologists regarding cytomegalovirus infection during pregnancy – United States, 2007. MMWR Morb Mortal Wkly Rep. 2008;57:65–8.Google Scholar
  191. 191.
    Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol. 2007;17:355–63.PubMedGoogle Scholar
  192. 192.
    Reynolds DW, Stagno S, Stubbs KG, Dahle AJ, Livingston MM, Saxon SS, et al. Inapparent congenital cytomegalovirus infection with elevated cord IgM levels. Casual relation with auditory and mental deficiency. N Engl J Med. 1974;290:291–6.PubMedGoogle Scholar
  193. 193.
    Bristow BN, O’Keefe KA, Shafir SC, Sorvillo FJ. Congenital cytomegalovirus mortality in the United States, 1990–2006. PLoS Negl Trop Dis. 2011;5:e1140.PubMedPubMedCentralGoogle Scholar
  194. 194.
    Rahav G, Gabbay R, Ornoy A, Shechtman S, Arnon J, Diav-Citrin O. Primary versus nonprimary cytomegalovirus infection during pregnancy, Israel. Emerg Infect Dis. 2007;13:1791–3.PubMedPubMedCentralGoogle Scholar
  195. 195.
    Hollier LM, Grissom H. Human herpes viruses in pregnancy: cytomegalovirus, Epstein-Barr virus, and varicella zoster virus. Clin Perinatol. 2005;32:671–96.PubMedGoogle Scholar
  196. 196.
    Varani S, Frascaroli G, Landini MP, Soderberg-Naucler C. Human cytomegalovirus targets different subsets of antigen-presenting cells with pathological consequences for host immunity: implications for immunosuppression, chronic inflammation and autoimmunity. Rev Med Virol. 2009;19:131–45.PubMedGoogle Scholar
  197. 197.
    Trincado DE, Rawlinson WD. Congenital and perinatal infections with cytomegalovirus. J Paediatr Child Health. 2001;37:187–92.PubMedGoogle Scholar
  198. 198.
    Cheeran MC, Lokensgard JR, Schleiss MR. Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention. Clin Microbiol Rev. 2009;22:99–126.PubMedPubMedCentralGoogle Scholar
  199. 199.
    Ross SA, Novak Z, Pati S, Boppana SB. Overview of the diagnosis of cytomegalovirus infection. Infect Disord Drug Targets. 2011;11:466–74.PubMedPubMedCentralGoogle Scholar
  200. 200.
    Bonalumi S, Trapanese A, Santamaria A, D’Emidio L, Mobili L. Cytomegalovirus infection in pregnancy: review of the literature. J Prenat Med. 2011;5:1–8.PubMedPubMedCentralGoogle Scholar
  201. 201.
    McCarthy FP, Jones C, Rowlands S, Giles M. Primary and secondary cytomegalovirus in pregnancy. Obstet Gynaecol. 2009;11:96–100.Google Scholar
  202. 202.
    Kimberlin DW, Lin C, Sanchez PJ, et al. Effect of ganciclovir therapy on hearing impairment in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr. 2003;143:16–25.PubMedGoogle Scholar
  203. 203.
    Centers for Disease Control and Prevention. Cytomegalovirus (CMV) and congenital CMV infection: prevention. 2010. Available from: http://www.cdc.gov/cmv/prevention.html.
  204. 204.
    Centers for Disease Control and Prevention. Cytomegalovirus (CMV) and congenital CMV infection: at-risk patients. 2010. Available from: http://www.cdc.gov/cmv/clinical/at-risk.html.
  205. 205.
    Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. The “silent” global burden of congenital cytomegalovirus. Clin Microbiol Rev. 2013;26:86–102.PubMedPubMedCentralGoogle Scholar
  206. 206.
    Papaloukas O, Giannouli G, Papaevangelou V. Successes and challenges in varicella vaccine. Ther Adv Vaccines. 2014;2:39–55.PubMedPubMedCentralGoogle Scholar
  207. 207.
    Zerboni L, Sen N, Oliver SL, Arvin AM. Molecular mechanisms of varicella zoster virus pathogenesis. Nat Rev Microbiol. 2014;12:197–210.PubMedPubMedCentralGoogle Scholar
  208. 208.
    Whitely RJ. Varicella-zoster virus. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 5th ed. New York: Churchill Livingstone; 2000. p. 1580–6.Google Scholar
  209. 209.
    Smith CK, Arvin AM. Varicella in the fetus and newborn. Semin Fetal Neonatal Med. 2009;14:209–17.PubMedGoogle Scholar
  210. 210.
    Enders G, Miller E, Cradock-Watson J, Bolley I, Ridehalgh M. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet. 1994;343:1548–51.PubMedGoogle Scholar
  211. 211.
    Preblud SR, Bregman DJ, Vernon LL. Deaths from varicella in infants. Pediatr Infect Dis. 1985;4:503–7.Google Scholar
  212. 212.
    Sauerbrei A, Wutzler P. Neonatal varicella. J Perinatol. 2001;21:545–9.PubMedGoogle Scholar
  213. 213.
    Rodríguez-Fanjul X, Noguera A, Vicente A, González-Enseñat MA, Jiménez R, Fortuny C. Herpes zoster in healthy infants and toddlers after perinatal exposure to varicella-zoster virus: a case series and review of the literature. Pediatr Infect Dis J. 2010;29:574–6.PubMedGoogle Scholar
  214. 214.
    Shrim A, Koren G, Yudin MH, Farine D, MFM Committee. Management of varicella infection (chickenpox) in pregnancy. J Obstet Gynaecol Can. 2012;34:287–92.PubMedGoogle Scholar
  215. 215.
    Therapeutic Guidelines. Varicella (chicken pox) (revised 2014). Etg complete [internet]. Melbourne: Therapeutic Guidelines Limited; 2014.Google Scholar
  216. 216.
    American Academy of Pediatrics. Varicella zoster infection. In: Pickering LK, editor. Red book online 2003: report of the committee on infectious diseases. 26th ed. Elk Grove Village: American Academy of Pediatrics; 2003. p. 672–86.Google Scholar
  217. 217.
    Flagg EW, Weinstock H. Incidence of neonatal herpes simplex virus infections in the United States, 2006. Pediatrics. 2011;127:e1–8.PubMedGoogle Scholar
  218. 218.
    Batra D, Davies P, Manktelow BN, Smith C. The incidence and presentation of neonatal herpes in a single UK tertiary centre, 2006–2013. Arch Dis Child. 2014;99:916–21.PubMedGoogle Scholar
  219. 219.
    Centers for Disease Control and Prevention. CDC fact sheet – genital herpes. 2013. Available from: http://www.cdc.gov/std/herpes/stdfact-herpes-detailed.htm.
  220. 220.
    Bradley H, Markowitz LE, Gibson T, McQuillan GM. Seroprevalence of herpes simplex virus types 1 and 2–United States, 1999–2010. J Infect Dis. 2014;209:325–33.PubMedGoogle Scholar
  221. 221.
    Looker KJ, Garnett GP, Schmid GP. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ. 2008;86:805–812, A.PubMedPubMedCentralGoogle Scholar
  222. 222.
    Wald A. Genital HSV-1 infections. Sex Transm Infect. 2006;82:189–90.PubMedPubMedCentralGoogle Scholar
  223. 223.
    Kimberlin DW. AAP clarifies approach to babies born to women with genital herpes lesions. AAP News. 2013;34:30.Google Scholar
  224. 224.
    James SH, Sheffield JS, Kimberlin DW. Mother-to-child transmission of herpes simplex virus. J Pediatr Infect Dis Soc. 2014;3:S19–23.Google Scholar
  225. 225.
    Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med. 1992;116:197–202.PubMedGoogle Scholar
  226. 226.
    Brown ZA, Benedetti J, Ashley R, et al. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med. 1986;315:796–800.Google Scholar
  227. 227.
    Brown ZA, Wald A, Morrow RA, et al. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA. 2003;289:203–9.PubMedGoogle Scholar
  228. 228.
    Arvin AM, Hensliegh PA, Prober CG, et al. Failure of antepartum maternal cultures to predict the infant’s risk of exposure to herpes simplex at delivery. N Engl J Med. 1986;315:796–800.PubMedGoogle Scholar
  229. 229.
    Hill J, Roberts S. Herpes simplex virus in pregnancy: new concepts in prevention and management. Clin Perinatol. 2005;32:657–70.PubMedGoogle Scholar
  230. 230.
    Natale F, Bizzarri B, Castronovo A, Russo A, Bartolucci M, Pedicino R, et al. Neonatal herpes simplex infection. Early Hum Dev. 2013;89:S73–5.Google Scholar
  231. 231.
    Kimberlin DW. Neonatal herpes simplex infection. Clin Microbiol Rev. 2004;17:1–13.PubMedPubMedCentralGoogle Scholar
  232. 232.
    Whitely RJ, Corey L, Arvin A, et al. Changing presentation of herpes simplex virus infection in neonates. J Infect Dis. 1988;158:109–16.Google Scholar
  233. 233.
    Enright AM, Prober CG. Herpesviridae infections in newborns: varicella zoster virus, herpes simplex virus, and cytomegalovirus. Pediatr Clin North Am. 2004;51:889–908.PubMedGoogle Scholar
  234. 234.
    White DO, Fenner FJ. Herpes simplex viruses in Herpesviridae. Medical virology. 4th ed. San Diego: Academic; 1994. p. 323–30.Google Scholar
  235. 235.
    Dasgupta G, Chentoufi AA, Kalantari M, Falatoonzadeh P, Chun S, Lim CH, et al. Immunodominant “asymptomatic” herpes simplex virus 1 and 2 protein antigens identified by probing whole-orfome microarrays with serum antibodies from seropositive asymptomatic versus symptomatic individuals. J Virol. 2012;86:4358–69.PubMedPubMedCentralGoogle Scholar
  236. 236.
    Kimberlin DW, Lin CY, Jacobs RF, Powell DA, Frenkel LM, Gruber WC, et al. Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics. 2001;108:223–9.PubMedGoogle Scholar
  237. 237.
    Nahmias AJ. Neonatal hsv infection. Part 1: Continuing challenges. Herpes. 2004;11:33–7.PubMedGoogle Scholar
  238. 238.
    Pinninti SG, Kimberlin DW. Management of neonatal herpes simplex virus infection and exposure. Arch Dis Child Fetal Neonatal Ed. 2014;99:F240–4.PubMedGoogle Scholar
  239. 239.
    Singh A, Preiksaitis J, Ferenczy A, Romanowski B. The laboratory diagnosis of herpes simplex virus infections. Can J Infect Dis Med Microbiol. 2005;16:92–8.PubMedGoogle Scholar
  240. 240.
    Allen UD, Robinson JL. Prevention and management of neonatal herpes simplex virus infections. Paediatr Child Health. 2014;19:201–12.PubMedPubMedCentralGoogle Scholar
  241. 241.
    Runnegar N. HSV in pregnancy. Obstet Gynaecol Mag. 2012;14:18–9.Google Scholar
  242. 242.
    Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 2006;20:73–83.PubMedGoogle Scholar
  243. 243.
    Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med. 2011;1:a006841.PubMedPubMedCentralGoogle Scholar
  244. 244.
    Moodley J, Moodley D. Management of human immunodeficiency virus infection in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2005;19:169–83. Review.PubMedGoogle Scholar
  245. 245.
    Campbell-Yesufu OT, Gandhi RT. Update on human immunodeficiency virus (HIV)-2 infection. Clin Infect Diseas. 2011;52:780–7.Google Scholar
  246. 246.
    Engelman A, Cherepanov P. The structural biology of HIV-1: mechanistic and therapeutic insights. Nat Rev Microbiol. 2012;10:279–90.PubMedPubMedCentralGoogle Scholar
  247. 247.
    Coffin J, Swanstrom R. HIV pathogenesis: dynamics and genetics of viral populations and infected cells. Cold Spring Harb Perspect Med. 2013;3:a012526.PubMedPubMedCentralGoogle Scholar
  248. 248.
    Nyamweya S, Hegedus A, Jaye A, Rowland-Jones S, Flanagan KL, Macallan DC. Comparing HIV-1 and HIV-2 infection: lessons for viral immunopathogenesis. Rev Med Virol. 2013;23:221–40.PubMedGoogle Scholar
  249. 249.
    American Academy of Pediatrics. Red book online. Elk Grove Village: American Academy of Pediatrics; 2012. Available from: http://redbook.solutions.aap.org/.Google Scholar
  250. 250.
    National HIV Testing Policy Expert Reference Committee. 2011 National HIV Testing Policy v1.3: Australasian Society for HIV Medicine. 2013.Google Scholar
  251. 251.
    Loutfy MR, Margolese S, Money DM, Gysler M, Hamilton S, Yudin MH, et al. Canadian HIV pregnancy planning guidelines. J Obstet Gynaecol Can. 2012;34:575–90.PubMedGoogle Scholar
  252. 252.
    Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States – 2014. Atlanta: Centers for Disease Control and Prevention; 2014.Google Scholar
  253. 253.
    European AIDS Clinical Society. European AIDS Clinical Society: HIV treatment guidelines. Version 7.0. 2013.Google Scholar
  254. 254.
    Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (updated november 2013.) HIV Med. 2014;15:1–85.Google Scholar
  255. 255.
    Ioannidis JP, Abrams EJ, Ammann A, Bulterys M, Goedert JJ, Gray L, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J Infect Dis. 2001;183:539–45.PubMedGoogle Scholar
  256. 256.
    World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013.Google Scholar

Copyright information

© Springer International Publishing 2015

Authors and Affiliations

  • C. R. Robert George
    • 1
  • Monica M. Lahra
    • 1
  • Heather E. Jeffery
    • 2
    Email author
  1. 1.South Eastern Area Laboratory Services, NSW Health PathologyThe Prince of Wales HospitalRandwickAustralia
  2. 2.International Maternal and Child HealthSydney School Public Health, University of Sydney, Royal Prince Alfred HospitalCamperdownAustralia

Personalised recommendations